プロリンクス、眼中薬物送達システムの評価における第一三共との協力を発表
June 19, 2017 09:00 ET
|
ProLynx LLC
サンフランシスコ発, June 19, 2017 (GLOBE NEWSWIRE) -- プロリンクス (ProLynx LLC) は本日、同社の眼中での薬物送達リンカー技術を評価するために、第一三共株式会社 (Daiichi Sankyo Company, Limited) と協力することを発表した。 ...
プロリンクス、glp-1受容体アゴニストの月1回投与をサポートするハイドロゲル･ミクロスフェア薬物送達システム、「plx039」を発表
June 12, 2017 14:55 ET
|
ProLynx LLC
サンフランシスコ, June 13, 2017 (GLOBE NEWSWIRE) -- サンディエゴで開催中の米国糖尿病学会第77回会議の最新の要旨において、プロリンクス (ProLynx LLC) は、2型糖尿病 (T2D) の治療のためのGLP-1受容体アゴニスト (GLP-1RA) の月1回の皮下 (SC)...
ProLynx announces PLX039, a hydrogel-microsphere drug delivery system that supports once-monthly administration of a GLP-1 receptor agonist
June 12, 2017 09:00 ET
|
ProLynx LLC
SAN FRANCISCO, June 12, 2017 (GLOBE NEWSWIRE) -- In a late-breaking abstract at the 77th American Diabetes Association meeting in San Diego, ProLynx LLC announced a novel drug delivery system to...
ProLynx issued US patent for cleavable linker technology on hydrogels
May 30, 2017 20:03 ET
|
ProLynx LLC
SAN FRANCISCO, May 30, 2017 (GLOBE NEWSWIRE) -- ProLynx LLC today announced that the United States Patent and Trademark Office has issued US Patent 9,649,385 entitled “Hydrogels with Biodegradable...
ProLynx Awarded NSF Supplement to Develop Its Hydrogel Drug Delivery System to Treat Inner Ear Disorders
June 29, 2015 17:21 ET
|
ProLynx LLC
SAN FRANCISCO, June 29, 2015 (GLOBE NEWSWIRE) -- ProLynx LLC, a biotechnology company focused on development of disruptive drug delivery systems for half-life extension, announced the receipt of a...
ProLynx Announces Active IND of a Novel Ultra-Long Acting PEG–SN-38 Conjugate to Treat Solid Tumors
June 02, 2015 14:05 ET
|
ProLynx LLC
SAN FRANCISCO, June 02, 2015 (GLOBE NEWSWIRE) -- ProLynx LLC announced today that an Investigational New Drug (IND) application for their novel, ultra-long acting PEG~SN-38 (PLX-0264; DFP-13318)...
ProLynx Issued Key Patent for Using Releasable Linkers on Insoluble Carriers
February 04, 2015 10:04 ET
|
ProLynx LLC
SAN FRANCISCO, Feb. 4, 2015 (GLOBE NEWSWIRE) -- ProLynx LLC, a biotechnology company focused on development of a novel platform for half-life extension of injectable drugs – peptides, proteins...
ProLynx Awarded NSF Phase II Grant for Controlled Drug Release From and Degradation of Hydrogels
November 13, 2014 10:00 ET
|
ProLynx LLC
SAN FRANCISCO, Nov. 13, 2014 (GLOBE NEWSWIRE) -- ProLynx LLC, a biotechnology company focused on development of disruptive drug delivery systems for half-life extension of injectable drugs, today...
ProLynx Issues U.S. Patent Covering Controlled Release Drug Conjugates
June 17, 2014 16:00 ET
|
ProLynx LLC
SAN FRANCISCO, June 17, 2014 (GLOBE NEWSWIRE) -- ProLynx LLC, a biotechnology company focused on development of disruptive drug delivery systems for half-life extension of injectable drugs, today...
RxGen and ProLynx Present Data on Ocular Delivery Platform
May 13, 2014 10:00 ET
|
ProLynx LLC
SAN FRANCISCO, May 13, 2014 (GLOBE NEWSWIRE) -- RxGen and ProLynx LLC, presented primate study data showing that polyethylene glycols (PEGs) are appropriate supports to extend ocular pharmacokinetics...